On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)' 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker's board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped out nearly $30 billion in market value and erased all of the stock's 2026 gains following back-to-back clinical trial failures. Artisan's David Samra told Reuters that "the party is over" and urged Chairman Giovanni Caforio to change the team overseeing dealmaking, though he stopped short of blaming CEO Vas Narasimhan, saying he has done "a very good job" since taking over in 2018.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.